-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6

Benzinga·10/08/2026 15:25:59
语音播报
Wells Fargo analyst Yanan Zhu upgrades Editas Medicine (NASDAQ:EDIT) from Equal-Weight to Overweight and raises the price target from $4 to $6.